NCT03143621

Brief Summary

Post-operative ileus ("post-op ileus") is a condition which can occur after surgery. This means that the bowels stop working correctly and food and liquids will not pass through in the normal manner. Post-op ileus can be uncomfortable and require a longer hospital stay until the bowels begin to function correctly again. Currently there are no effective methods for preventing post-op ileus. Some studies suggest there is a benefit from drinking coffee following colon or gynecological cancer surgeries with very little risk. However, the effects of coffee following small bowel surgery have not been studied. This randomized, controlled trial will compare the outcomes of patients who receive coffee during their hospital stay after small bowel surgery to similar patients who receive warm water. About 60 patients will be in each group. The main outcomes are time until the nasogastric tube is removed and length of hospital stay.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
79

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 18, 2017

Completed
20 days until next milestone

First Posted

Study publicly available on registry

May 8, 2017

Completed
6 months until next milestone

Study Start

First participant enrolled

November 15, 2017

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 13, 2022

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
Last Updated

August 16, 2023

Status Verified

August 1, 2023

Enrollment Period

4.2 years

First QC Date

April 18, 2017

Last Update Submit

August 15, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time to removal of nasogastric tube

    Time at placement to Time at removal through study completion

    From date of hospital admission up to date of hospital discharge (anticipated up to 2 weeks)

Secondary Outcomes (2)

  • Time to return of bowel function

    From date of hospital admission up to date of hospital discharge (anticipated up to 2 weeks)

  • Length of Stay

    From date of hospital admission up to date of hospital discharge (anticipated up to 2 weeks)

Study Arms (2)

Coffee

EXPERIMENTAL

100 cc's of coffee administered three times per day until return to bowel function has been established.

Dietary Supplement: Coffee

Water

PLACEBO COMPARATOR

100 cc's of warm water administered three times per day until return to bowel function has been established.

Other: Water

Interventions

CoffeeDIETARY_SUPPLEMENT

Brewed, caffeinated coffee, 100 cc's each dose

Coffee
WaterOTHER

Tap water heated to same temperature as coffee

Water

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing small bowel resection. Can be elective, urgent or emergent.

You may not qualify if:

  • Patient with atrial fibrillation who is considered a non-coffee drinker (drinks coffee less than 3 days per week over the last 4 weeks)
  • Patients undergoing colon resection without removal of any portion of small bowel.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mount Carmel Health System

Columbus, Ohio, 43213, United States

Location

MeSH Terms

Interventions

CoffeeWater

Intervention Hierarchy (Ancestors)

Plant PreparationsBiological ProductsComplex MixturesBeveragesDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesHydroxidesAlkaliesInorganic ChemicalsAnionsIonsElectrolytesOxidesOxygen Compounds

Study Officials

  • Fernando Aguila, MD

    Mount Carmel Health System

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Patients will not be told what group they are assigned to, however, complete masking will be difficult to achieve. The patient's treatment assignment is part of the medical record.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Randomized, parallel-group, controlled clinical trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 18, 2017

First Posted

May 8, 2017

Study Start

November 15, 2017

Primary Completion

January 13, 2022

Study Completion

September 30, 2022

Last Updated

August 16, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

There is no plan to share individual patient data at this time.

Locations